Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Inhibitor Therapeutics, Inc. (INTI) had Return on Equity of -20629.26% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-0.71M |
|
-- |
|
-- |
|
$0.74M |
|
$-0.74M |
|
$0.03M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.74M |
|
$-0.74M |
|
172.57M |
|
172.57M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$3.06M |
|
-- |
|
$0.07M |
|
$3.14M |
|
$0.09M |
|
-- |
|
$3.04M |
|
$3.13M |
|
$0.00M |
|
$0.00M |
|
$0.00M |
|
172.57M |
|
| Cash Flow Statement Financials | |
$-2.63M |
|
-- |
|
-- |
|
$5.61M |
|
$2.98M |
|
$-2.63M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
35.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-20629.26% |
-20626.41% |
|
-22.72% |
|
-20625.08% |
|
$0.00 |
|
$-0.02 |
|
$-0.02 |
|